Q-omics provides the consensus-scored ARHGAP35 profile across patient tissues and cancer cell-line models. ARHGAP35 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARHGAP35 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ARHGAP35 protein abundance shows 22,358 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where ARHGAP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP35 survival associations across molecular data types. ARHGAP35 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP35 RNA expression–survival associations across cancer types. High ARHGAP35 expression shows unfavorable associations in MESO, ACC, OV and LIHC, but favorable associations in KIRC and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARHGAP35 RNA expression.
This table summarizes ARHGAP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP35 shows lower tumor expression in THCA, COAD, LUAD and KIRP and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher ARHGAP35 RNA expression in tumor versus normal tissue (log2 FC = +0.559, t-test p < 0.001).
This table shows molecular features associated with ARHGAP35 in patient tissues and cancer cell lines. In patient samples, ARHGAP35 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
